Tafinlar/Mekinist (dabrafenib/trametinib)
pCPA File Number:
21132
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0152-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: